While the present work presents the first epigenomic and transcriptomic characterization of the genetic program induced by the C11orf95-RELA fusion protein, future works on additional ST-EPN-RELA cell lines and primary tumors will further establish the core program as well as subtype differences critical for the development of precision and personalized therapeutics for this devastating cancer. The gene discussed is RELA; the disease is cancer.